Gynecology & obstetrics (Sunnyvale, Calif.)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?

Pub Date : 2021-01-01 Peter G Rose, Laura M Chambers, Michelle Kuznicki

The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).

Pub Date : 2021-01-01 Peter G Rose, Meng Yao, Laura M Chambers, Lin Mei, Phuc Le

Chemotherapy for Elderly Ovarian Cancer Patients

Pub Date : 2016-08-01 DOI: 10.4172/2161-0932.1000397 Sivraj Muralikrishnan, C. Hatzis, A. Katz, A. Santin, P. Schwartz, M. Abu-Khalaf